Want to see ES:ATRY full AI Analyst Report?
Top Page
Atrys Health SA
(BME:ATRY)
Select Model
Select Model
Rating:43Neutral
Price Target:
€2.50
▼(-2.34% Downside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by weak financial performance (persistent losses, negative free cash flow, and deterioration in 2025) and a negative P/E that reflects ongoing unprofitability. Technicals provide only limited support, showing a short-term improvement but a broader downtrend versus longer-term moving averages.
Positive Factors
Business model / Structural demand
Atrys focuses on radiation oncology and medical diagnostics paid through reimbursements and service contracts. That structural exposure to essential oncology care and contracted payments supports recurring revenue streams and patient volumes, making core demand less cyclical and more durable over months.
Negative Factors
Persistent operating losses
Operating losses across periods, culminating in a much larger 2025 loss, show the company has not converted gross profit into sustainable operating profitability. Ongoing deficits erode equity, limit reinvestment, and require recurring financing or structural cost reductions to avoid long-term viability issues.
Read all positive and negative factors
Positive Factors
Negative Factors
Business model / Structural demand
Atrys focuses on radiation oncology and medical diagnostics paid through reimbursements and service contracts. That structural exposure to essential oncology care and contracted payments supports recurring revenue streams and patient volumes, making core demand less cyclical and more durable over months.
Read all positive factors
Atrys Health SA (ATRY) vs. iShares MSCI Spain ETF (EWP)
Market Cap
€191.47M
Dividend YieldN/A
Average Volume (3M)19.78K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth-33.72%
EPS Growth-215.75%
CountryES
Employees553
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.32
Shares Outstanding76,014,190
10 Day Avg. Volume15,409
30 Day Avg. Volume19,783
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.47
Price to Sales (P/S)1.58
P/FCF Ratio-15.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.01
Revenue Forecast (FY)€198.00M
Atrys Health SA Business Overview & Revenue Model
Company Description
Atrys Health, S.A., a biomedical enterprise founded in 2007 and based in Madrid, Spain, specializes in providing a range of diagnostic services and medical treatments. Its diagnostic portfolio encompasses areas like pathology, hematology, molecula...
How the Company Makes Money
Atrys Health makes money primarily by providing healthcare services and being paid for those services, with revenues largely tied to (1) oncology-related clinical activity—most notably radiation oncology treatments delivered through its network of...
Atrys Health SA Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
52
Neutral
Cash Flow
29
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 141.01M | 212.74M | 201.57M | 158.37M | 121.01M |
| Gross Profit | 61.35M | 145.38M | 141.77M | 24.20M | 100.89M |
| EBITDA | -9.96M | 19.07M | 31.91M | 16.63M | 5.87M |
| Net Income | -100.30M | -31.77M | -45.59M | -23.15M | -23.20M |
Balance Sheet | |||||
| Total Assets | 494.04M | 584.19M | 629.00M | 705.28M | 565.63M |
| Cash, Cash Equivalents and Short-Term Investments | 17.76M | 29.29M | 42.18M | 35.84M | 41.70M |
| Total Debt | 257.87M | 166.13M | 254.00M | 241.22M | 154.95M |
| Total Liabilities | 342.08M | 330.95M | 339.12M | 367.71M | 291.65M |
| Stockholders Equity | 151.86M | 253.10M | 289.87M | 337.63M | 274.03M |
Cash Flow | |||||
| Free Cash Flow | -14.08M | -10.14M | -547.00K | -30.59M | -3.87M |
| Operating Cash Flow | -1.56M | 3.00M | 5.70M | -15.43M | 4.69M |
| Investing Cash Flow | -12.59M | -12.95M | 395.00K | -80.59M | -2.45M |
| Financing Cash Flow | 11.28M | -11.51M | 8.19M | 94.77M | 14.08M |
Atrys Health SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | €220.34M | 13.54 | 12.34% | 4.08% | 4.20% | -10.44% | |
69 Neutral | €1.48B | 25.57 | 23.64% | 1.22% | 15.52% | 34.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €228.99M | -89.55 | -2.23% | ― | ― | 53.50% | |
43 Neutral | €191.47M | -1.88 | -51.00% | ― | -33.72% | -215.75% |
* Healthcare Sector Average
ES:ATRY
Atrys Health SA
2.50
-0.33
-11.66%
ES:ORY
Oryzon Genomics SA
2.79
<0.01
0.29%
ES:PHM
Pharma Mar SA
82.20
-4.69
-5.40%
ES:IKM
1nKemia IUCT Group SA
0.31
0.00
0.00%
ES:PRM
PRIM, S.A.
12.95
1.14
9.65%
ES:LAB
Labiana Health SA
6.20
2.28
58.00%
Atrys Health SA Corporate Events
Atrys Health Reports Strong Quorum and Approved Resolutions at 2026 Shareholders’ Meeting
Jun 24, 2026
Atrys Health disclosed the results of its Ordinary General Shareholders’ Meeting held on 18 June 2026 in Madrid, where shareholders approved all resolutions presented by the board. The meeting was convened in compliance with EU and Spanish s...
Atrys boosts profitability, slashes debt and expands oncology footprint in Q1 2026
May 22, 2026
Atrys Health reported first-quarter 2026 revenue of 37.5 million euros, up 6.3% year-on-year, while EBITDA rose 15.4% to 4.1 million, driven by strong gains in Oncology, Nuclear Medicine and Diagnostic Imaging, particularly in Mexico and Portugal....
Atrys Health Boosts Q1 Profitability and Slashes Debt as International Oncology Business Accelerates
May 22, 2026
Atrys Health posted first-quarter 2026 revenue of 37.5 million euros, up 6.3% year on year, while EBITDA rose 15.4% to 4.1 million, driven by strong gains in Oncology, Nuclear Medicine and Diagnostic Imaging, particularly in Mexico and Portugal. T...
Atrys Health Lifts Q1 2026 Earnings, Cuts Debt and Deepens Oncology Focus
May 22, 2026
Atrys Health SA reported solid first-quarter 2026 results, with revenue up 6.3% and EBITDA rising 15.4% year on year, driven by strong performances in Portugal, Latin America and especially Mexico, as well as double-digit growth in radiology and r...
Atrys Health Names Veteran Finance Executive Alberto Iriondo as New CFO to Drive Next Growth Phase
May 6, 2026
Atrys Health has appointed Alberto Iriondo as its new Chief Financial Officer and member of the Executive Committee, reinforcing its leadership team at a time of balance sheet strengthening, debt reduction and sharper focus on core strategic busin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.